ACC: AstraZeneca's Farxiga chops follow-up CV events by 16% in heart attack patients with diabetes

ACC: AstraZeneca's Farxiga chops follow-up CV events by 16% in heart attack patients with diabetes

Submitted by admin on March 18, 2019 - 12:16pm
Source: 
Fierce Pharma
News Tags: 
AstraZeneca
Farxiga
American College of Cardiology
Headline: 
ACC: AstraZeneca's Farxiga chops follow-up CV events by 16% in heart attack patients with diabetes
snippet: 

After AstraZeneca released overall CV outcomes results for Farxiga, the company has dug further into the data and presented two subanalyses on Monday.

Do Not Allow Advertisers to Use My Personal information